Cargando…

1690. Oral Fosfomycin for the Treatment of Bacterial Prostatitis

BACKGROUND: Bacterial prostatitis (BP) is notoriously difficult to treat. Few antibiotics penetrate the prostate well, and antibiotic resistance can further restrict options. A small body of recent literature suggests fosfomycin, a bactericidal antibiotic that can treat multidrug resistant (MDR) org...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamath, Meghan, Johns, Scott T, Ma, Ariel, Mehta, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778002/ http://dx.doi.org/10.1093/ofid/ofaa439.1868

Ejemplares similares

Oral fosfomycin for the treatment of chronic bacterial prostatitis
por: Karaiskos, Ilias, et al.
Publicado: (2019)

1239. Ceftaroline versus Vancomycin as First-Line Therapy for MRSA Bacteremia
por: Kamath, Meghan, et al.
Publicado: (2021)

65. Impact of a Multifaceted Stewardship Intervention on Oral Fosfomycin Prescribing for Treatment of Resistant Organisms in Cystitis
por: Pry, Marie, et al.
Publicado: (2020)

Oral fosfomycin for treatment of acute bacterial prostatitis caused by multidrug-resistant Enterobacterales
por: Burgos, Joaquin, et al.
Publicado: (2023)

1690. Assessing the safety of TP-102 bacteriophage treatment in the management of diabetic foot infections
por: Nir-Paz, Ran, et al.
Publicado: (2022)

P1690: NEUTROPHIL EXTRACELLULAR TRAP (NET) LEVELS IN COVID-19 PATIENTS
por: López De Frutos, L., et al.
Publicado: (2022)

1690. Risk Factors of Invasive Aspergillosis in Systemic Lupus Erythematosus Patients
por: Kunawathanakul, Sithichai, et al.
Publicado: (2019)

1242. Efficacy and Safety of Intravenous Fosfomycin for the Treatment of Multi-resistant Gram Negative Infections
por: Abdallah, Tasneem, et al.
Publicado: (2021)

Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli
por: Zhanel, George G., et al.
Publicado: (2018)

1222. Fosfomycin Susceptibility Testing using the new ETEST(®)FO
por: Halimi, Diane, et al.
Publicado: (2020)

Johannes Schmiedt (1623–1690)
por: Pekacka-Falkowska, Katarzyna, et al.
Publicado: (2021)

Christian Goldbach 1690–1764
por: Juškevič, Adolf P, et al.
Publicado: (1994)

COLLABORATION AGREEMENT No. K 1690
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2009)

1417. Fosfomycin Use in the Treatment of Complicated Urinary Tract Infections at a Veterans Affairs Medical Center
por: Lee, Ryan, et al.
Publicado: (2021)

611. Fosfomycin Resistance of Multidrug-Resistant Escherichia coli and Mechanisms of Fosfomycin Resistance
por: Seok, Hyeri, et al.
Publicado: (2019)

P1690: SHARED DECISION-MAKING IN MULTIPLE MYELOMA: DO PATIENTS, CAREGIVERS, AND PHYSICIANS SHARE THE SAME GOALS AND PREFERENCES?
por: Dwyer, Lisa, et al.
Publicado: (2023)

1690. Acute Hematogenous Osteoarticular Infections in Children at Siriraj Hospital, Thailand: A 20-Year Retrospective Review
por: lertamornkitti, nichkamol, et al.
Publicado: (2023)

2412. Our Experience With IV Fosfomycin
por: Savaj, Pratik, et al.
Publicado: (2018)

192. The Use of Area Under the Curve to Determine Therapeutic Vancomycin Dosing in Skin and Soft Tissue Infections
por: Dea, Lauren, et al.
Publicado: (2020)

2261. Oral Fosfomycin for Treatment of Urinary Tract Infections Due to Extended-Spectrum β-Lactamase and Carbapenem-Resistant Enterobacteriaceae
por: Hefler, Jade L, et al.
Publicado: (2019)

1386. Efficacy of Repeat Dosing of Oral Fosfomycin in a Dynamic Bladder Infection In Vitro Model
por: Abbott, Iain, et al.
Publicado: (2018)

1526. Oral Fosfomycin Use for Urinary Tract Infections and Its Clinical Impact on Hospital Stay
por: Mai, Christina, et al.
Publicado: (2018)

60. Evaluation of Outcomes Associated with Intermittent Versus Extended Infusion of Piperacillin/tazobactam in Acutely Ill Veterans
por: Encarnacion, Marianne Angeli, et al.
Publicado: (2020)

Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations
por: Marino, Andrea, et al.
Publicado: (2022)

2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017
por: Snayd, Mary, et al.
Publicado: (2018)

1049. Weight Gain in Persons Living with HIV (PLWH) Treated with Bictegravir Compared to Other Integrase Strand Transfer Inhibitors
por: Fang, Michelle, et al.
Publicado: (2020)

Pharmacokinetics and Metabolism of Ziritaxestat (GLPG1690) in Healthy Male Volunteers Following Intravenous and Oral Administration
por: Helmer, Eric, et al.
Publicado: (2021)

652. Comparison of fosfomycin (FOF) activity and prevalence of subpopulations between Escherichia coli (EC) and Klebsiella pneumoniae (KP) during susceptibility testing
por: Anderson, Jadyn C, et al.
Publicado: (2020)

976. Population Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analysis of Intravenous Fosfomycin for Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

1690 Opportunities for Improved Detection and Treatment of Latent Tuberculosis Infection Among Veterans — Western United States, January 2010–July 2013
por: Perti, Tara, et al.
Publicado: (2014)

International Symposium on Huygens Principle: 1690-1990, Theory and Applications
Publicado: (1990)

Oral and Intravenous Fosfomycin for the Treatment of Complicated Urinary Tract Infections
por: Zhanel, George G., et al.
Publicado: (2020)

Highly Contiguous Nanopore Genome Assembly of Chlamydomonas reinhardtii CC-1690
por: O’Donnell, Samuel, et al.
Publicado: (2020)

674. Variations in Agreement and Epidemiological Cutoff Value (ECV) between Fosfomycin (FOF) Agar Dilution and Broth Microdilution Using Standard- and High-Inoculum Protocols for Klebsiella pneumoniae (KP)
por: Krueger, Amanda R, et al.
Publicado: (2020)

Bacterial sensitivity to fosfomycin in pregnant women with urinary infection
por: Souza, Rodrigo Batista, et al.
Publicado: (2015)

2062. Evaluation of Susceptibility Testing Methods for Fosfomycin Against Enterobacteriaceae and Pseudomonas aeruginosa
por: De La Cadena, Elsa Piedad, et al.
Publicado: (2018)

Fosfomycin Pharmacokinetic Profile in Plasma and Urine and Quantitative Estimation in Prostate and Seminal Vesicles after One and Two Consecutive Doses of Oral Fosfomycin Trometamol in Healthy Male Volunteers
por: Di Stefano, Andrea F. D., et al.
Publicado: (2022)

Evidence of a large cooling between 1690 and 1740 AD in southern Africa
por: Sundqvist, H. S., et al.
Publicado: (2013)

First observation of the $\Xi^{-}\pi^{+}$ decay mode of the $\Xi(1690)^{0}$ hyperon
por: Adamovich, M I, et al.
Publicado: (1998)

First observation of the $\Xi^{-} \pi^{+}$ decay mode of the $\Xi^{0}(1690)$ hyperon
por: Adamovich, M.I., et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_7ip3gn5c5tma1mdt9bkkm64brp